Huntington’s Disease
Huntington’s disease, also known as Huntington’s chorea, is a hereditary neurodegenerative disorder that affects both the brain and the body. It is named after Dr. George Huntington, who first described the condition in the late 19th century.
Huntington’s disease is caused by a genetic mutation in the huntingtin gene (HTT), which leads to the production of abnormal huntingtin protein. The mutation involves an abnormal repetition of the CAG trinucleotide within the gene, causing an expansion of the repeating sequence. The more repeats a person has, the earlier and more severe the onset of the disease tends to be.
This magazine contains content which is gathered, validated, categorized, and supplied using a novel big data cyberinfrastructure technology that continually learns about Huntington’s Disease.
-
Publication date: Mar 03, 2026 In Huntington’s disease (HD), disease-driver genes are broadly expressed, but ...
-
Neurizon Expands NUZ-001 Huntington’s Disease Data at ASENT 2026
Publication date: Mar 05, 2026 The results support a dual mechanism of improved proteostasis and ... -
Neurizon Expands NUZ-001 Huntington’s Disease Data at ASENT 2026
Publication date: Mar 05, 2026 The results support a dual mechanism of improved proteostasis and ... -
A moderate-intensity exercise program during inpatient rehabilitation for middle stage Huntington’s disease: A randomized controlled trial.
Publication date: Mar 03, 2026 BackgroundExercise is beneficial for persons with Huntington’s disease (HD). Inpatient ... -
Enhancing the detection of HTT1a with neoepitope antibodies in mouse models of Huntington’s disease
Publication date: Mar 02, 2026 Huntington’s disease is an inherited neurodegenerative disorder caused by a ... -
Molecular Dynamics Simulations Reveal PolyQ-Length-Dependent Conformational Changes in Huntingtin Exon-1: Implications for Environmental Co-Solvent Modulation of Aggregation-Prone States
Publication date: Mar 02, 2026 Huntington’s disease (HD) is caused by CAG-repeat expansion in HTT, ... -
Vorinostat Rescues SQSTM1 Palmitoylation and Restores Dysfunctional Autophagy in Huntington Disease
Publication date: Mar 02, 2026 Protein mislocalization, impaired autophagy, and protein aggregation are central features ... -
FDA requests additional clinical trial of Huntington’s gene therapy AMT-130
Publication date: Mar 04, 2026 Accelerated, or conditional, approval allows experimental therapies to reach the ... -
Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
Publication date: Mar 04, 2026 While its not fully approved, it allows access as soon ... -
A moderate-intensity exercise program during inpatient rehabilitation for middle stage Huntington’s disease: A randomized controlled trial.
Publication date: Mar 03, 2026 BackgroundExercise is beneficial for persons with Huntington’s disease (HD). Inpatient ... -
Berbamine hydrochloride as a brain penetrant galectin 3 inhibitor in a model of Huntington’s disease.
Publication date: Mar 03, 2026 Galectin-3 (Gal3) acts as an intracellular sensor of lysosomal damage ... -
Huntington’s disease LIG1 modifier variant increases ligase fidelity and suppresses somatic CAG repeat expansion.
Publication date: Mar 10, 2026 Huntington’s disease (HD) is a fatal neurodegenerative disorder caused by ... -
Metformin improves RAN protein pathology, alternative splicing, and behavioral phenotypes in SCA8 mice.
Publication date: May 01, 2026 Spinocerebellar ataxia type 8 (SCA8) is a member of a ... -
New Tech Tracks Living Brain Activity Noninvasively
Publication date: Mar 02, 2026 This tells scientists how the brain is physically changing in ... -
Roflumilast Elicits Therapeutic and Neuroprotective Effects in 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Neurodegeneration in Rats by Mitigating NLRP3 Inflammasome-Mediated Pyroptosis, Ferroptosis, and Glial Activation.
Publication date: Feb 28, 2026 Open Access PDF Concepts Keywords Disease Cell death Huntington Gasdermin ... -
HAP1 interaction with KCNQ4 attenuates channel surface expression and function.
Publication date: Mar 01, 2026 The voltage-gated channel subfamily Q member 4 (KCNQ4), a K+ ... -
Contribution of neuroepigenetics to HD – developmental and aging-related signatures.
Publication date: Feb 27, 2026 Huntington’s disease (HD) is a neurodegenerative disorder triggered by an ... -
Abnormal cortical development sets the stage in Huntington disease.
Publication date: Feb 27, 2026 One of the great mysteries of Huntington disease (HD) is ... -
Genetic or pharmacological disruption of the MSH3 Y245/K246 IDL binding pocket slows CAG repeat expansion
Publication date: Feb 26, 2026 Recent genetic studies have shown somatic expansion of the CAG ... -
The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington disease.
Publication date: Feb 24, 2026 The pathogenic mechanisms leading to neurodegeneration in Huntington disease (HD) ... -
Silmitasertib, an FDA-designated orphan CK2 inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington’s disease mouse model.
Publication date: Feb 24, 2026 Huntington’s disease (HD) is a devastating autosomal dominant neurodegenerative disease ...